Laman UtamaGRAL • NASDAQ
add
Grail Inc
Tutup sebelumnya
$17.73
Julat hari
$17.23 - $17.71
Julat tahun
$12.33 - $24.92
Permodalan pasaran
593.24J USD
Bilangan Purata
982.76K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | 28.65J | 38.27% |
Perbelanjaan pengendalian | 175.74J | -12.27% |
Pendapatan bersih | -125.69J | 85.90% |
Margin untung bersih | -438.67 | 89.80% |
Pendapatan bagi setiap syer | -3.50 | — |
EBITDA | -125.27J | 18.72% |
Kadar cukai berkesan | 27.10% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 853.55J | — |
Jumlah aset | 3.12B | — |
Jumlah liabiliti | 530.32J | — |
Jumlah ekuiti | 2.59B | — |
Syer tertunggak | 33.60J | — |
Harga kepada buku | 0.23 | — |
Pulangan pada aset | -12.88% | — |
Pulangan pada modal | -15.14% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -125.69J | 85.90% |
Tunai daripada operasi | -104.58J | 33.60% |
Tunai daripada pelaburan | -971.00K | 68.36% |
Tunai daripada pembiayaan | 0.00 | -100.00% |
Perubahan bersih dalam tunai | -105.29J | -21.33% |
Aliran tunai bebas | -36.90J | — |
Perihal
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential. Wikipedia
Diasaskan
2015
Ibu pejabat
Tapak web
Pekerja
1,170
